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Abstract
The majority of neurodegenerative diseases have an important age component, and thus,
understanding the molecular changes that occur during normal aging of the brain is of utmost
relevance. In search for the basis of the age-related cognitive decline found in humans, monkeys
and rodents, we study the rhesus monkey. Surprisingly, there is no loss of neurons in aged monkey
brains. However, we reported white matter and myelin abnormalities in aged monkeys, similar to
those observed in Alzheimer’s disease and multiple sclerosis patients. In a microarray analysis
comparing young and old monkey white matter, we discovered that Klotho is downregulated in
the aged brain. We then asked whether there is a connection between the age-related cognitive
decline, myelin abnormalities and Klotho downregulation. If such a connection is found,
compounds that upregulate Klotho expression could become of therapeutic interest for the
treatment of multiple sclerosis, and perhaps even Alzheimer’s disease.
One of the enormous challenges facing modern medicine is the treatment of
neurodegenerative diseases. Neurons are post-mitotic cells and once they are born in utero
they have to last a lifetime. A long list of genetic and environmental insults can weaken and
kill neurons. Therefore, our goal is to identify reagents that are neuroprotective and would
rescue these amazingly active cells from premature death. The most prevalent
neurodegenerative diseases are Alzheimer’s disease (AD), Parkinson’s disease (PD),
Huntington disease (HD) and amyotrophic lateral sclerosis (ALS). In the last 30 years, in
rare cases of these disorders, mutations, gene duplications, expanded triple repeats or
deletions have been identified and demonstrated to cause either autosomal dominant or
recessive inheritability. However, except for HD, which is always dominantly inherited, the
majority of AD, PD and ALS cases are called sporadic or idiopathic, meaning that one
genetic cause has not been elucidated or that multiple genes with low individual effects
interact to cause disease. Although not considered a typical neurodegenerative disease
because neurons are not the direct target of destruction, multiple sclerosis (MS) results from
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progressive insults on myelin of the CNS resulting in neurological symptoms. MS is an
autoimmune disease in which the white matter myelin is attacked by the immune system
leading to demyelination and axonal injury.
In AD, PD, HD and ALS selective neuronal populations are the victims of an, as of yet,
unknown attack or lack of a protecting factor, as seen by the plethora of manifestations that
bring the patient to a neurologist. From memory loss and cognitive decline to tremor and
muscle weakness, these diseases always incapacitate the patients and shorten their lifespan
causing a heavy psychological and financial strain to family members. With an increasing
aging population these diseases also exert tremendous burden on national health care
systems.
In this article we will focus on a less traveled path in neurodegenerative diseases, the
abnormalities in the form of demyelination vastly seen in the white matter in MS, to a lesser
extent in AD and during normal aging. Next, we will examine the role of Klotho protein on
brain white matter, strategies to augment expression of this protein as a means of potential
therapy for the treatment of demyelinating neurodegenerative diseases and our recent efforts
to identify small molecules that increase Klotho at the transcriptional level.
Features of neurodegenerative diseases relevant to the role of Klotho
AD is the most prevalent form of dementia among the elderly. The major neuropathological
findings in AD are the presence of amyloid β (Aβ) plaques, neurofibrillary tangles, brain
atrophy, and synaptic and neuronal loss. Currently, Aβ, a proteolytically derived fragment of
the amyloid precursor protein, is recognized as a major initiating factor in the cascade of
events that leads to progressive neurodegeneration in AD with evidence from multiple
laboratories of its toxicity towards neurons and their synapses [1]. However, only the
reduction of Aβ levels, currently being tried in multiple clinical studies, would prove that
indeed Aβ is the culprit in AD. Meanwhile, other potential pathways responsible for
neurodegeneration need to be considered in AD and other diseases. The greatest known risk
factor for AD is increasing age. One out of eight people over 65 years of age have AD and
nearly half of all people over 85 years of age have AD. Thus, studying factors that
contribute to aging is of utmost importance. We focused our interest on the normal aging of
the brain in the rhesus monkey, an animal model that develops cognitive decline with age
similarly to humans.
In aged white matter, but not the gray matter of these nonhuman primates, we have detected
neuroinflammation in the form of activated microglia [2] and reactive astrocytes [3]. In
addition, we have observed attack on myelin by the complement system [4], the activation
of the calcium-activated cysteine proteinase, calpain, an enzyme known to degrade
cytoskeletal proteins [5,6] and abnormalities of the Node of Ranvier [7]. All these results
indicating white matter degeneration complement the ultra-structural studies demonstrating
age-related dysmyelination [8].
By MRI, the white matter in AD patients exhibits areas of hypomyelination seen as hyper-
intensities. One hundred times less prevalent than AD, multiple sclerosis (MS) is an
inflammatory demyelinating disease of the central nervous system that often progresses to
significant chronic disability. Impaired remyelination is a common pathologic feature of MS
and may largely account for disability and incomplete remissions in MS [9]. Several groups
have established that remyelination is incomplete in MS lesions, despite numerous
oligodendrocyte precursor cells (OPCs) found within and near the lesions [10–12]. Thus, a
factor that would induce OPC maturation may be missing or an inhibitor of myelination is
overactive [13].
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Klotho, the anti-aging protein
Klotho is a recently discovered protein with profound effects on health and lifespan in
mammals [14,15]. In mice, Klotho overexpression extends lifespan, while its disruption
accelerates aging-like phenotypes, including atherosclerosis, osteoporosis, infertility and
cognitive decline. Thus, a reduction in Klotho level is detrimental to the entire organism.
Klotho is mainly expressed in the brain and in the kidney where it plays an antioxidative
function and controls calcium and phosphate homeostasis. In addition, Klotho has been
shown to have anti-inflammatory [16,17] and tumor suppressor properties [18]. Klotho is
expressed as a type I transmembrane protein that is shed by ADAM10 and 17 [19] and is
detectable in serum and cerebrospinal fluid [20]. The transmembrane form of Klotho has
been shown to act as a coreceptor with FGF receptors to facilitate high affinity signaling of
FGF23 in the kidney. The shed form of Klotho has been shown to possess many functions,
including suppression of insulin/IGF1 and wnt signaling [21] and regulation of calcium and
phosphate homeostasis (Table 1) [22,23]. Interestingly, shed Klotho can act as a ligand to
an, as yet, unknown receptor to transduce signaling in the target cell, or as a glycosidase to
modify a receptor or ion channel as shown for the TRPV5 channel [24,25]. Indeed, the
extracellular domain of Klotho has homology to the family 1 glycosidases, which are
enzymes that hydrolyze terminal glycosidic linkages in sugars, glycoproteins and
glycolipids.
The anti-aging properties of Klotho are also associated with increased resistance to oxidative
stress [15] and inflammation [17]. The possible link between Klotho and the inflammatory
cytokines, such as TNF, was shown previously. Klotho’s downregulation is associated with
increased inflammation in kidney [16], inflammatory bowel disease [26] and rheumatoid
arthritis [27]. Klotho is known for the suppression of TNF-α-induced expression of adhesion
molecules in a model of endothelial inflammation [28]. This effect of Klotho was
accompanied by the attenuation of NF-κB activation, IκB phosphorylation and inhibition of
eNOS phosphorylation induced by TNF-α. The protective effect of Klotho through the
negative regulation of NF-κB signaling was demonstrated also in the model of inflammation
in diabetic kidneys [16] and kidney injury [29]. The mechanism of protection involves the
inhibition of RelA Ser-536 phosphorylation as well as promoter DNA binding of this
phosphorylated form of RelA [16]. In future studies we will explore in our experimental
system the possibility of the involvement of the inhibition of NF-κB signaling in the
mechanism of Klotho protection from TNF cytotoxicity.
Recently, clinical phenotypes of loss-of-function mutations in human Klotho were reported.
A 13-year-old girl with a homozygous missense mutation (H193R) of the Klotho gene
exhibited decreased expression and secretion of Klotho protein resulting in osteopenia, but
not neuropsychiatric symptoms [30]. The authors concluded that the loss-of-function
mutations in human Klotho impair FGF23 bioactivity, underscoring the essential role of
Klotho in FGF23-mediated phosphate and vitamin D homeostasis in humans. In the Klotho-
hypomorphic mouse, the degeneration of mesencephalic dopaminergic neurons was
observed that was related to increased vitamin D exposure [31]. Klotho has been shown to
inhibit 1-α hydroxylase, the enzyme responsible for the production of 1,25 dihydroxy
vitamin D3, the active vitamin D [32]. Thus, lower Klotho levels in these hypomorphic mice
induced vitamin D production and toxicity, and this toxicity was rescued by vitamin D
restriction. So far, this mechanism of Klotho function has only been shown in the kidney.
Nevertheless, the finding that lower levels of Klotho are toxic to organs other than the brain
supports the idea that increasing Klotho levels would be beneficial.
In the brain, Klotho is highly expressed in the choroid plexus and in neurons, especially in
the hippocampus (Figure 1), as well as in the kidney and reproductive organs [14]. However,
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in contrast with the kidney, where the function of Klotho has been elucidated as shown in
Table 1, in brain, the precise function and signaling pathways of Klotho are entirely
unknown [15,25,33–36]. The neural Klotho may play a role in the aging phenotypes and
protect against the development of age-related neurodegenerative diseases. In humans, the
Klotho-VS variant is associated with reduced longevity and reasoning abilities, and mice
lacking Klotho develop cognitive deficits [37–40]. We have previously reported that Klotho
is downregulated in the brain white matter of normally aging rhesus monkeys [41]. This
decrease in Klotho [41] correlated with age-related myelin loss and damage observed in the
monkey brains [4–7,42] and was also seen in brains of aged rats and mice. Interestingly,
brains from an AD mouse model exhibited Klotho expression that was even lower than that
of their age-matched littermates. At the ultrastructural level, Klotho-knockout mice have
significantly decreased myelination of the optic nerve and corpus callosum and,
biochemically, brains of knockout mice express lower levels of myelin mRNAs and proteins
[Chen et al. The anti-aging protein klotho enhances oligodendrocyte maturation and
myelination of the central nervous system (2012), Submitted Manuscript]. We reported that
one of the reasons for the age-dependent downregulation of Klotho is the increased
methylation of its GC rich promoter [43]. Interestingly, the augmented methylation when
compared with young animals was observed in the white matter of aged rhesus monkeys, but
not in their gray matter.
We have recently shown that in cell culture, Klotho enhances the maturation of OPCs into
mature oligodendrocytes [Chen et al. The antiaging protein klotho enhances oligodendrocyte
maturation and myelination of the central nervous system (2012), Submitted Manuscript].
Neuropathologically, Klotho-deficient mice display characteristics of neuronal degeneration
in the cortex [14,44] and hippocampus [44]. Thus, it appears that the absence of only one
gene has a major impact on the health and function of neurons and oligodendrocytes.
Furthermore, increases in Klotho may rescue the phenotypes observed in the aging brain and
in neurodegenerative diseases. Therefore, given the age-dependent decline in Klotho
expression, combined with its multiple age-related deficiencies, has prompted us to explore
therapeutic strategies that would augment Klotho expression in the brain for the treatment of
demyelinating neurodegenerative diseases, such as MS and AD. When identified, Klotho-
enhancing compounds could also alleviate other severe disorders where Klotho is
downregulated, including all cancers tested to date by expression profiling (see [101] for
details) and chronic kidney disease [23].
Strategies for modulating Klotho levels
Several potential strategies can be envisioned to increase the brain’s level of Klotho. First is
direct delivery of exogenous Klotho. However, the introduction of this 130 kDa protein into
the brain is prohibitive due to its molecular weight and its inability to cross the blood–brain
barrier. Alternatively, identification of small orally bioavailable molecules that can cross the
blood–brain barrier and that increase Klotho levels would be preferable. These molecules
could affect Klotho levels or Klotho-dependent signaling pathways via several possible
mechanisms. For example, molecules could act as Klotho mimetics by binding and
activating, as yet unknown, receptors, or they could increase Klotho DNA transcription or
protein translation or decrease Klotho degradation. With the lack of knowledge with regard
to Klotho signaling pathways finding mimetics is not currently a viable strategy. However,
the remaining strategies are all reasonable options that could provide useful probes for
further understanding Klotho’s role in both normal physiology and in various
neurodegenerative conditions.
Recently, we have initiated a program to identify small molecules that would increase
Klotho at the transcriptional level. These efforts included devising a high-throughput screen
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(HTS) to identify compounds that increase Klotho protein expression. This assay was then
utilized to screen over 150,000 compounds. The resulting compounds will be useful in
future studies to determine whether Klotho-enhancing molecules could alleviate
neurodegenerative changes that occur in aging and disease, specifically in MS and AD
animal models. Although the molecular mechanisms by which Klotho enhancement may
alleviate the MS or AD course of disease could be different, the resulting increase in Klotho
is expected to be beneficial in both conditions.
Assay for HTS
In order to identify small molecules that increase Klotho protein expression, we cloned the
1.8 kb of DNA immediately upstream of the Klotho translation start site into the pGL3
luciferase reporter vector. Stable cell lines were then generated by co-transfection of the
Klotho reporter with pcDNA3.1 into HEK-293 cells. The assay was miniaturized to a 384-
well format and an initial compound, N-phenyl-1H-indole-2-carboxamide, was identified in
a validation set of compounds as being able to elevate luciferase expression by ~30% and
served as a positive control for screening. The remaining laboratory for drug discovery in
neurodegeneration (LDDN) library of ~150,000 compounds (assembled from various
commercial and noncommercial sources and enriched for compounds with predicted brain
permeability based on low-molecular-weight, cLogP, and relatively low numbers of
hydrogen bond donors and acceptors) were tested at a concentration of 1 μM for the ability
to increase luciferase expression as a marker of Klotho promoter activation. After the screen,
hits were defined as any compound causing at least a 30% increase in luciferase expression.
A total of 414 compounds or 0.27% of all compounds met this threshold of activation. All
414 compounds were retested at five concentrations (2–0.02 μM) to validate the molecule as
a hit and to obtain an initial indication of dose-dependent response. Two hundred
compounds were selected for further study and prioritized based on potency, dose response
and chemical structure (i.e., lack of reactive functional groups, molecular weight <500,
cLogP <5 and synthetic feasibility).
Compounds that had been identified in other luciferase-based HTS campaigns conducted at
the laboratory for drug discovery in neurodegeneration were removed from further
consideration to concentrate on only those that affect Klotho expression as opposed to being
nondiscriminant enhancers of gene transcription. Of the 50 compounds prioritized for
further characterization, 38 were available for reordering from their original source. Fresh
stocks were utilized to ensure the initial hit was not a side product of freeze–thaw
degradation or some other contaminating byproduct specific to an individual lot. Fresh
stocks were applied to the HTS platform at 12 concentrations (30–0.0001 μM). Luciferase
expression and cell cytotoxicity assays were performed in parallel to examine both
activation and toxicity. None of the compounds tested showed evidence of toxicity at any of
the concentrations examined. Thirty of 38 compounds tested in 12-point dose–response
assays revealed dose-dependent profiles. These were further prioritized to ten compounds
based on dose–response and compound structure for additional validation with qRT-PCR.
All of these compounds range in molecular weight from 288–410, have a cLogP value <5
(except one, which is 5.6) and lack overtly reactive functional groups. The majority of these
compounds are quite tractable as lead compounds for optimization. However, based on the
initial biological findings (i.e., qRT-PCR and western blot analyses) two structurally
unrelated hits, compounds 21 and 25, have been selected for initial optimization studies and
eight unselected compounds represent possible back-up molecules [45]. All of these
compounds could eventually provide useful probes for elucidating mechanisms related to
Klotho transcriptional control.
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Validation of compounds in cell culture
Since the HTS was performed on a promoter luciferase construct, it is crucial to prove that
Klotho protein expression and function are also increased. For protein expression opossum
kidney cells or choroid plexus cells were used because these cells have detectable levels of
Klotho and they represent the organs (i.e., kidney and brain, respectively) that express
Klotho endogenously. In both these cell types, the two selected compounds enhanced Klotho
protein expression as seen by western blot analysis. For the functional analysis of Klotho we
have developed an assay in which we detect phosphorylated ERK in response to Klotho in
cells transfected with the FGFR1c receptor and with the addition of FGF23. Klotho has been
previously reported to be a co-receptor for FGFR1 and is needed for the high-affinity
binding of FGF23 to the receptor [46]. Furthermore, to rule out the possibility that another
protein was responsible for ERK phosphorylation, cells were treated with Klotho siRNA and
the ERK phosphorylation was almost entirely abolished. Finally, to prove that these
compounds work at the transcriptional level, Klotho mRNA was significantly increased, as
assessed by qRT-PCR, following treatment with compounds [45]. In summary, our lead
compounds identified in the HTS are inducing endogenous Klotho mRNA and protein
expression, and this elevated Klotho is physiologically active.
Current efforts & future plans for compounds that enhance Klotho
transcription
The Klotho promoter–luciferase assay was an artificial system used in the HTS to identify
Klotho-enhancing compounds and, hence, a more physiologic assay to demonstrate the
efficacy of the lead compounds was necessary, and since the last publication we have
conducted some further analysis. These initial tests and data suggest promise, but the results
are preliminary with full experimental data and methods to be verified and published at a
later date. A short discussion has been provided below. We wished to determine whether we
can take advantage of our recent finding that Klotho induces OPC maturation and test the
compounds in an OPC maturation assay. However, we discovered that among the rat
primary neural cell tested for Klotho expression by western blot, OPCs do not express
detectable levels of Klotho, while astrocytes and neurons do. We then decided to use co-
cultures of primary astrocytes and OPCs with the assumption that the compounds would
increase Klotho expression in the astrocytes, which would then secrete Klotho. The shed
astrocytic-derived Klotho would then bind to an, as of yet, unknown receptor on OPCs to
induce their maturation. As a control for the experiment we used the recombinant shed form
of Klotho that we previously showed is able to induce OPC maturation acting as a humoral
factor. Compound 21 (identified and prioritized from the HTS assay) and recombinant
Klotho induced the expression of myelin basic protein, a well-accepted marker of OPC
maturation, while compound 25 only showed a trend towards this effect. To prove that these
compounds acted via induction of Klotho mRNA expression, primary rat hippocampal
neurons and astrocytes were individually treated with compounds 21 and 25 and Klotho
mRNA expression was assessed by qRT-PCR. Figure 2 shows that both compounds
enhanced Klotho promoter–luciferase activity. We used concentrated Klotho shed into the
conditioned medium of HEK293 cells over-expressing the extracellular 980 amino acids of
Klotho. This secreted form of Klotho was able to rescue from cell death co-cultures of
oligodendrocytes and astrocytes treated with TNF-α at two different concentrations. Based
on these results we examined whether compounds 21 and 25 could also rescue these glial
cells from inflammatory stress induced by TNF-α. Indeed, both compounds significantly
reduced cell death in this assay, as shown in Figure 3. With these results in hand, we are
encouraged to investigate the anti-inflammatory potential of Klotho and Klotho-enhancing
compounds on other neuroinflammatory paradigms.
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Currently, SAR studies are ongoing for the two prioritized compounds. A large number of
analogs for both series have been purchased and tested in the Klotho promoter-luciferase
assay. Those with nanomolar EC50 are being tested for their efficacy to induce OPC
maturation. Based on the preliminary SAR results and the results from the neural cell assays,
novel Klotho-enhancing compounds are now being synthesized with the aims to increase
potency, improve solubility and maximize brain permeability and pharmacokinetic
properties. Future plans include testing analogs in animal models of AD and MS. In
addition, these compounds will be useful for elucidating the mechanism of action for
increasing Klotho levels via enhancing Klotho transcription.
Conclusion
The absence of a single gene in mice causes a plethora of age-related manifestations
including osteoporosis, infertility, emphysema, arteriosclerosis, hair loss, cognitive
impairment, synaptic loss and premature death at an average 60 days [14]. Interestingly,
Klotho-deficient mice exhibit hallmarks of human aging, but develop normally until 40 days
of age. Thus, it appears that Klotho is not needed during development but its deficiency in
adulthood and late life leads to multiple organ failure and early death. Indeed, we reported
that Klotho protein is downregulated in the aged brains of monkeys, rats and mice [41], and
to an even higher extent in animal models of AD. In situ hybridization studies described in
the Allen Atlas of the mouse brain [102] indicate that Klotho is highly expressed in the
choroid plexus and in hippocampal neurons. Thus, the brain is bathed in cerebrospinal fluid
that contains high concentrations of Klotho in addition to the local expression found in
neurons. Mice lacking Klotho exhibit neurodegeneration of their hippocampal neurons [44]
suggesting that in this region of the brain Klotho may act as a protective autocrine hormone,
and its absence induces neuronal loss. Klotho shed by neurons or originating from the
choroid plexus may also affect the differentiation of OPCs into mature, myelinating
oligodendrocytes. Thus, based on our results, we posit that Klotho is a neuroprotective
hormone/factor that is downregulated with age and compounds that could elevate its
concentration in the brain would be beneficial in the treatment of demyelinating and
neurodegenerative diseases. Although various strategies can be envisioned as means to
increase Klotho levels in the brain, our efforts to date have been focused on the
identification, optimization and biological characterization of small molecules that increase
Klotho gene transcription. These molecules and potentially others that operate via alternate
mechanisms will be valuable pharmacological probes of Klotho regulation in normal
physiology and also for evaluation in animal models of demyelination such as MS, and in
animal models of AD. Such compounds could also be studied in additional mouse models of
neurodegenerative diseases, including PD, HD and ALS. We hope that Klotho, which was
only discovered in 1997, will become a major player in the ongoing fight against
neurodegenerative diseases.
Future perspective
Our ability to prevent or cure neurodegenerative diseases is very limited or inexistent at this
time. However, these conditions share many common characteristics such as abnormally
folded proteins, inflammation and selective neuronal death. Just like in the treatment of
cardiovascular diseases, where antihypertensive and cholesterol-lowering drugs are
prescribed, we may need a cocktail of drugs to treat age-related neurodegeneration. We hope
that over the next 5–10 years Klotho-enhancing compounds will prove to be neuroprotective
and will be one of the drugs used in concert with protein aggregation-lowering drugs and
anti-inflammatory drugs to prevent and alleviate neurodegenerative diseases.
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Key Terms
Alzheimer’s
disease
Most common form of dementia in the elderly
Multiple sclerosis Inflammatory disease in which the fatty myelin sheaths around the
axons of the brain and spinal cord are damaged, leading to
demyelination and scarring as well as a broad spectrum of symptoms
Myelin Fatty sheath surrounding the axons, which is necessary for the rapid
communication between nerve cells
Inflammation Protective attempt by the organism to remove injurious stimuli such
as pathogens, damaged cells or irritants, and to initiate the healing
process
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Executive summary
• There are a number of features of neurodegenerative diseases relevant to the role
of Klotho, especially in Alzheimer’s disease and multiple sclerosis.
• Strategies for modulating Klotho levels are discussed and assays for high-
throughput screening commented on. Following this, the compounds were
validated in the cell culture.
• Future work includes further validation of compounds in physiologic cell-based
assays and in animal models of neurodegenerative diseases.
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Figure 1. Sagittal view of Klotho mRNA distribution in mouse brain demonstrated by in situ
hybridization
Note that the highest expression is in the choroid plexus, followed by hippocampal neurons,
especially those in CA1. Reproduced from [102].
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Figure 2. Compounds 21 and 25 induce Klotho mRNA expression
(A) The increase in luciferase signal is specific to KL promoter activation. (B) Time course
of KL promoter activation in HEK293 cells stably transfected with a KL promoter-luciferase
construct. q-PCR analysis of KL expression induced by the compounds in (C) primary
hippocampal neurons and (D) in primary astrocytes.
KL: Klotho.
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Figure 3. Concentrated endogenously secreted Klotho and compounds 21 and 25 rescue co-
cultures of oligodendrocyte precursor cells and astrocytes from TNF-α-induced cytotoxicity
Cells were pretreated with compounds for 24 h or with concentrated Klotho for 4 h and then
exposed to 50 or 100 ng/ml of TNF-α for an additional 24 h. Cell cytotoxicity was assessed
by CellTiter-Glo® (Promega).
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Table 1
Pleiotropic functions of secreted Klotho protein.
Glycoproteins regulated by secreted Klotho Klotho effects Ref.
Ion channels
Transient receptor potential vanilloid type isoform-5 Increase in Ca2+ influx [25]
Transporters
Renal outer medullary potassium channel-1 Increase in K+ efflux [33]
Na-dependent phosphate co-transporter, type-IIa Decrease in Pi influx [34]
Pit-1, 2 (Na-dependent phosphate co-transporter, type-III) Decrease in Pi influx [35]
Receptors
IGF-1 receptors Inhibition [15]
TGF-β1 receptor (type-II) Inhibition [36]
Modified with permission from [23].
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